Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 2NIH 1FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Neoplasm Metastasis 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Healthy Participants 2Uterine Cervical Neoplasms 1Solid Tumour 1Recurrence 1Ovarian Neoplasms 1Moderate Hepatic Impairment 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1Endometrial Neoplasms 1Disease Progression 1Advanced Solid Tumours 1Advanced Solid Malignancy, 1Advanced Solid Malignancy 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × capivasertib × Clear all
NCT04493853 2026-05-05

CAPItello-281

AstraZeneca

Phase 3 Active not recruiting
1,012 enrolled
Genitourinary

Prostatic Neoplasms

NCT05348577 2025-01-27

CAPItello280

AstraZeneca

Phase 3 Active not recruiting
1,035 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

AstraZeneca

Phase 1 Completed
27 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡